ABIVAX Société Anonyme (NASDAQ:ABVX) Reaches New 12-Month Low – What’s Next?

ABIVAX Société Anonyme (NASDAQ:ABVX)’s stock price reached a new 52-week low on Tuesday . The stock traded as low as $8.27 and last traded at $8.39, with a volume of 8114 shares. The stock had previously closed at $8.50.

ABIVAX Société Anonyme Stock Up 0.7 %

The firm has a fifty day moving average price of $10.17 and a 200 day moving average price of $11.82.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Point72 Asset Management L.P. grew its holdings in ABIVAX Société Anonyme by 28.2% during the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock worth $6,254,000 after purchasing an additional 119,300 shares during the period. Walleye Capital LLC lifted its position in shares of ABIVAX Société Anonyme by 45.8% in the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after buying an additional 80,807 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of ABIVAX Société Anonyme by 82.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after acquiring an additional 5,900 shares during the period. abrdn plc increased its holdings in shares of ABIVAX Société Anonyme by 167.7% during the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock worth $3,645,000 after acquiring an additional 198,225 shares during the last quarter. Finally, Janus Henderson Group PLC raised its stake in ABIVAX Société Anonyme by 18.2% in the 1st quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock valued at $12,113,000 after acquiring an additional 131,414 shares during the period. Institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.